

Retatrutide sodium salt

Chemical Properties

CAS No. :

Formula:

Molecular Weight:

Storage:

Store at low temperature, Keep away from moisture

Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Actual storage temperature shall be subject to the COA.

Retatrutide sodium
salt (2381089-83-2
free base)

Biological Description

Description	Retatrutide sodium salt is a potent triple agonist peptide for glucagon receptor (GCGR), glucose-dependent proinsulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R) Retatrutide sodium salt is used in the study of type 2 diabetes and obesity.
Targets(IC50)	Glucagon Receptor
In vitro	Retatrutide sodium salt exhibits activity against human GCGR, GIPR, and GLP-1R, with EC50 values of 5.79, 0.0643, and 0.775 nM, respectively[1]. In mouse models, Retatrutide sodium salt demonstrates activity against GCGR, GIPR, and GLP-1R, with EC50 values of 2.32, 0.191, and 0.794 nM, respectively[1]. The binding affinities of Retatrutide sodium salt for human GCGR, GIPR, and GLP-1R are characterized by Ki values of 5.6, 0.057, and 7.2 nM, respectively[1]. For mouse GCGR, GIPR, and GLP-1R, Retatrutide sodium salt exhibits binding affinities with Ki values of 73, 2.8, and 1.3 nM, respectively[1].
In vivo	Retatrutide sodium salt, administered via subcutaneous injection at a single dose of 0.47 mg/kg, engages with the glucagon receptor (GCGR) in vivo and improves glucose tolerance in an intraperitoneal glucose tolerance test (ipGTT) through activation of GIP or GLP-1 receptors[1]. With subcutaneous injections at a dose of 10 mL/kg every 3 days for a cycle of 21 days, Retatrutide sodium salt induces significant weight loss and increased energy expenditure through activation of the glucagon-like peptide-1 (GLP-1) receptor[1]. Retatrutide sodium salt demonstrates safety and tolerability in these studies[1].

Reference

Tamer Coskun, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metab. 2022 Sep 6;34(9):1234-1247.e9.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286

E_mail:info@targetmol.com

Address:34 Washington Street,Wellesley Hills,MA 02481